Renal Solutions Inc.
This article was originally published in Start Up
Executive Summary
While in-home dialysis offers quality of life benefits for patients with kidney failure and even clinical benefits over in-center hemodialysis sessions, most conventional hemodialysis systems aren't suitable for the home environment. Renal Solutions has developed a self-contained hemodialysis system that is cost-effective and easy to use, to address the $1.6 billion potential market for home dialysis.
You may also be interested in...
Renal Devices: New Blood Revitalizes Dialysis Industry
CMS pays 33% of its budget for patients with end stage kidney disease, a group that, in terms of patient numbers, accounts for less than 1% of the Medicare population. For all this money spent, mortality rates remain high--the one year mortality rate for patients on hemodialysis stands at 24%, a survival rate that's worse than that of metastatic cancer. In an industry traditionally resistant to change, however, changes are coming, brought about by reimbursement changes and a delivery model that can't scale-up to meet a growing population, making room for new start-ups in the space.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.